CSL is a global biotechnology company founded in Australia in 1916 as Commonwealth Serum Laboratories. Over more than a century, it has grown into one of the larger players in the life sciences sector, employing over 29,000 people and supplying medicines and therapies to patients in more than 100 countries. The company invests billions in research and development across plasma protein technology, recombinant technology, cell and gene therapy, and vaccines.
CSL operates through three principal business units. CSL Behring focuses on biotherapies for rare and serious diseases, offering what it describes as the broadest range of plasma-derived and recombinant therapies. CSL Seqirus is one of the world's largest influenza vaccine providers, with a singular global focus on influenza prevention. CSL Vifor develops therapies for iron deficiency and nephrology. Supporting these units is CSL Plasma, the company's collection arm, which operates close to 350 centres across the United States, Europe, and China.
The company's technical work spans a broad set of domains relevant to biotechnology professionals:
- Plasma-derived and recombinant biotherapies
- Influenza vaccine development and manufacturing
- Cell and gene therapy
- Iron deficiency and nephrology treatments
- Large-scale plasma collection operations
CSL traces its origins to early public health contributions in Australia, including providing access to insulin, penicillin, and vaccines. Today it operates as a publicly listed company with a global footprint spanning research, manufacturing, and commercial functions across more than 100 countries.
